Infinimmune announced a research collaboration agreement with Immunome (IMNM) for the discovery and optimization of novel antibodies. Under the agreement, Immunome will receive target exclusivity. Financial terms of the deal were not disclosed. Infinimmune rapidly optimizes and engineers early leads into high-fidelity, development-ready therapeutic candidates using its Glimpse and Anthrobody platforms.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNM:
- Immunome initiated with a Buy at Craig-Hallum ahead of near-term catalysts
- Immunome initiated with a Buy at Craig-Hallum
- Immunome’s Varegacestat: Promising Phase 3 Prospects and Competitive Edge in Desmoid Tumor Treatment
- Gap downgraded, Ulta upgraded: Wall Street’s top analyst calls
- Immunome initiated with an Outperform at Evercore ISI